BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 27, 2004
View Archived Issues
HGS' Albugon For Diabetes Nets $183M Deal With GSK
Human Genome Sciences Inc.'s Albugon for diabetes drew a development and commercialization deal worth up to $183 million with GlaxoSmithKline plc, which gets worldwide rights to albumin-glucagon-like peptide-1. (BioWorld Today)
Read More
Stem Cells Inc. Shares Sink On $22.5M Placement Deal
Read More
Kai Advances First Clinical Product With $28M Series A
Read More
EntreMed Partners TFPI Program With Affymax
Read More
Correction
Read More
Other News To Note
Read More